Flagship’s latest startup gets a name: Cellarity
Understanding the precise role an individual cell plays in the onset of disease is increasingly important in drug development. A new startup from venture firm Flagship Pioneering, Cellarity, is using single-cell sequencing to find new therapies for cancer and inflammatory disease, STAT’s Kate Sheridan writes.
The company, which is deep in stealth mode and has yet to announce a Series A, is using machine learning and AI to parse apart the differences in cell type. Notably, it brought on Chad Nusbaum, a sequencing expert at the Broad Institute, to serve as chief technology officer.
The company, which is deep in stealth mode and has yet to announce a Series A, is using machine learning and AI to parse apart the differences in cell type. Notably, it brought on Chad Nusbaum, a sequencing expert at the Broad Institute, to serve as chief technology officer.
No hay comentarios:
Publicar un comentario